New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Pair Eyewear
Series C in 2023
Pair Eyewear, founded in 2017 and based in New York, specializes in customizable eyeglasses for children. The company offers a unique product line that includes base frames, which are standard glasses, and top frames, which are snap-on fronts that can be easily changed to reflect a child's evolving interests and personalities. By leveraging an e-commerce platform, Pair Eyewear aims to transform the eyeglass experience into an engaging activity for children while simplifying the process for parents. The brand focuses on quality and affordability, providing eyewear that combines style with functionality, featuring hand-polished acetate frames and shatterproof polycarbonate lenses.
Evernow
Series A in 2022
Evernow is a provider of women's health care services focused on supporting women before, during, and after menopause. The company offers an online teleconsultation platform that connects users with specialized doctors and provides access to science-backed information and treatments. Through this platform, Evernow facilitates conversations about effective care for managing changing hormones, empowering women to lead longer and healthier lives.
Nitra
Seed Round in 2022
Nitra is a financial technology company focused on enhancing the healthcare industry through efficient and transparent solutions. The company offers a platform that provides machine learning-powered financial software, including credit cards, loans, accounts, payments, and expense management tailored for medical professionals. Nitra's tools help healthcare providers streamline their spending and manage payments in one centralized location, offering a clear overview of daily expenses. The Nitra Visa Business Card rewards users with benefits for every transaction and provides access to discounts through a network of partners. By simplifying accounting and receipt reconciliation, Nitra aims to support healthcare providers in balancing patient care with efficient practice management, delivering modern technology and dedicated support to the sector.
Waymark
Series A in 2022
Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.
Incarey
Series C in 2021
InCarey is a leading domestic comprehensive service platform focusing on the management of patients with chronic diseases and vertical diseases. It is committed to providing one-stop Internet medical, pharmaceutical, and medical services for patients with long-term, heavy-service, and high-value chronic diseases. Innovative payment services.
Pair Eyewear
Series B in 2021
Pair Eyewear, founded in 2017 and based in New York, specializes in customizable eyeglasses for children. The company offers a unique product line that includes base frames, which are standard glasses, and top frames, which are snap-on fronts that can be easily changed to reflect a child's evolving interests and personalities. By leveraging an e-commerce platform, Pair Eyewear aims to transform the eyeglass experience into an engaging activity for children while simplifying the process for parents. The brand focuses on quality and affordability, providing eyewear that combines style with functionality, featuring hand-polished acetate frames and shatterproof polycarbonate lenses.
Stride Health
Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.
Pager
Series C in 2021
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Shape Therapeutics
Series B in 2021
Shape Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Seattle, Washington. The company specializes in RNA-editing gene therapy targeting neurodegenerative disorders, oncology, metabolic conditions, and rare genetic diseases. Its proprietary RNAfix technology enables precise editing of RNA using the body's natural cellular mechanisms, which minimizes risks associated with immunogenicity, cellular toxicity, and off-target DNA editing. Shape Therapeutics employs a comprehensive approach to RNA gene therapy, integrating innovative payload, delivery, and manufacturing platform technologies. This strategy aims to facilitate the development of effective treatments and potential cures for a wide range of diseases, with the goal of enhancing patient outcomes across the healthcare landscape.
Vori Health
Series A in 2021
Vori Health is a healthcare provider focused on treating musculoskeletal conditions through an integrated care delivery model. Founded in 2020 and headquartered in New York, the organization offers a comprehensive range of services, including physical therapy, medical assessments, lab and imaging orders, health coaching, and nutritional guidance. Vori Health employs a virtual-first approach to connect patients with a collaborative care team, consisting of board-certified physical medicine physicians, health coach navigators, and physical therapists. This model aims to facilitate effective management of back, neck, and joint issues, guiding patients toward optimal wellness and recovery. By combining evidence-based practices with personalized support, Vori Health strives to improve patient outcomes in musculoskeletal care.
AllyAlign Health
Venture Round in 2021
AllyAlign Health operates as a care management company dedicated to supporting patients with chronic and complex medical conditions. Founded in 2013 and based in Glen Allen, Virginia, the company offers an active care management platform that facilitates real-time, collaborative care across various boundaries. This platform connects patients with care teams, providers, and community-based services, ensuring access to essential health information, care plans, and benefits necessary for informed decision-making. Users can easily view, share, create, and update information according to their roles and responsibilities, with mobile and web-based options enhancing accessibility for patients and their families. A central, HIPAA-compliant database consolidates information from multiple sources, including electronic health records and lab tests, while semantic data modeling provides meaningful clinical insights.
Vori Health
Series A in 2021
Vori Health is a healthcare provider focused on treating musculoskeletal conditions through an integrated care delivery model. Founded in 2020 and headquartered in New York, the organization offers a comprehensive range of services, including physical therapy, medical assessments, lab and imaging orders, health coaching, and nutritional guidance. Vori Health employs a virtual-first approach to connect patients with a collaborative care team, consisting of board-certified physical medicine physicians, health coach navigators, and physical therapists. This model aims to facilitate effective management of back, neck, and joint issues, guiding patients toward optimal wellness and recovery. By combining evidence-based practices with personalized support, Vori Health strives to improve patient outcomes in musculoskeletal care.
Personal Genome Diagnostics
Series C in 2021
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.
CVRx
Venture Round in 2020
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Pager
Series B in 2020
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Cardionomic
Venture Round in 2020
Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.
ChromaCode
Series C in 2019
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Shape Therapeutics
Series A in 2019
Shape Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Seattle, Washington. The company specializes in RNA-editing gene therapy targeting neurodegenerative disorders, oncology, metabolic conditions, and rare genetic diseases. Its proprietary RNAfix technology enables precise editing of RNA using the body's natural cellular mechanisms, which minimizes risks associated with immunogenicity, cellular toxicity, and off-target DNA editing. Shape Therapeutics employs a comprehensive approach to RNA gene therapy, integrating innovative payload, delivery, and manufacturing platform technologies. This strategy aims to facilitate the development of effective treatments and potential cures for a wide range of diseases, with the goal of enhancing patient outcomes across the healthcare landscape.
CVRx
Series G in 2019
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
GOQii
Series B in 2018
GOQii Inc. offers digital health and wellness solutions globally, primarily through its activity tracker wearables and a mobile application. The app monitors users' sleep, steps, active time, distance, and calories burned, while also providing features like caller ID, SMS and WhatsApp alerts, alarms, and notifications from health coaches. Users can connect with a range of health and fitness professionals, including nutritionists and personal trainers, who provide personalized advice based on individual health data via private chats or video calls. Additionally, the app facilitates access to medical consultations and diagnostic tests, allowing users to store health records securely in the cloud. Founded in 2013, GOQii is headquartered in Menlo Park, California, with additional offices in Mumbai and Shenzhen, and aims to promote healthier lifestyles through a combination of advanced technology and expert guidance.
MORE Health
Series C in 2018
MORE Health, Inc. operates a cloud-based physician collaboration platform aimed at connecting patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. The platform encompasses a comprehensive clinical database, including medical history, hospital records, lab results, and medical imaging, as well as discussion tools that facilitate HIPAA-compliant video conferencing. In addition to these features, MORE Health offers a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, the company now provides its services as a supplemental health benefit for U.S. companies, allowing employees to access high-quality medical consultations, including co-diagnoses and independent second opinions. Founded in 2013 and based in Foster City, California, MORE Health has established strategic alliances with notable medical institutions, aiming to serve patients globally and provide access to top medical expertise during critical health decision-making.
CareZone
Series D in 2018
CareZone is a healthcare platform that simplifies personal healthcare management and pharmacy delivery services. It offers tools to automate prescription refill reminders, track medical appointments, and manage health information for individuals and families. The platform allows users to coordinate care effectively by providing controlled access for family members and caregivers. By consolidating healthcare tasks into a single interface, CareZone enhances the ability of users to organize their health needs and streamline communication among those involved in their care.
Goop
Series C in 2018
Goop Inc. is a lifestyle brand that operates an online platform offering wellness advice, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop began as a newsletter sharing travel recommendations, health-focused recipes, and shopping finds, which has since evolved into a comprehensive lifestyle site. The platform features a selection of products including apparel, beauty items, skincare, and home goods, all sourced with an emphasis on quality and wellness. In addition to retail, Goop provides a wealth of digital content, such as beauty and makeup tips, cooking recipes, and wellness advice, along with travel information and design inspiration. By connecting its audience with expert insights and curated product offerings, Goop positions itself as a trusted resource for lifestyle enhancement.
MORE Health
Series B in 2018
MORE Health, Inc. operates a cloud-based physician collaboration platform aimed at connecting patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. The platform encompasses a comprehensive clinical database, including medical history, hospital records, lab results, and medical imaging, as well as discussion tools that facilitate HIPAA-compliant video conferencing. In addition to these features, MORE Health offers a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, the company now provides its services as a supplemental health benefit for U.S. companies, allowing employees to access high-quality medical consultations, including co-diagnoses and independent second opinions. Founded in 2013 and based in Foster City, California, MORE Health has established strategic alliances with notable medical institutions, aiming to serve patients globally and provide access to top medical expertise during critical health decision-making.
CTI BioPharma
Post in 2018
CTI BioPharma Corp. is a biopharmaceutical company headquartered in Seattle, Washington, that specializes in the development and commercialization of targeted therapies for blood-related cancers. The company is advancing its lead product, pacritinib, an investigational oral kinase inhibitor currently in Phase III clinical trials for myelofibrosis, a type of bone marrow cancer. In addition to pacritinib, CTI BioPharma's development portfolio includes Pixantrone, which is in a Phase III trial for non-Hodgkin's lymphoma, and Brostallicin, currently undergoing a Phase II study for sarcoma. The company has established collaboration and licensing agreements with various pharmaceutical firms, including Teva Pharmaceutical Industries Ltd. and Novartis International Pharmaceutical, Ltd. Founded in 1991, CTI BioPharma aims to deliver innovative and less toxic cancer therapies to patients.
Pager
Series A in 2018
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Personal Genome Diagnostics
Series B in 2018
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.
Stride Health
Series B in 2017
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.
ChromaCode
Series B in 2017
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.
Pager
Venture Round in 2016
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Goop
Series B in 2016
Goop Inc. is a lifestyle brand that operates an online platform offering wellness advice, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop began as a newsletter sharing travel recommendations, health-focused recipes, and shopping finds, which has since evolved into a comprehensive lifestyle site. The platform features a selection of products including apparel, beauty items, skincare, and home goods, all sourced with an emphasis on quality and wellness. In addition to retail, Goop provides a wealth of digital content, such as beauty and makeup tips, cooking recipes, and wellness advice, along with travel information and design inspiration. By connecting its audience with expert insights and curated product offerings, Goop positions itself as a trusted resource for lifestyle enhancement.
Personal Genome Diagnostics
Series A in 2015
Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.
Cardionomic
Series A in 2015
Cardionomic treats reduced cardiac output – ADHF’s root cause – by neuromodulating the terminal branches of the cardiac plexus to benignly increase contractility. Cardionomic’s acute, non-systemic therapy will improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Concurrently the therapy also achieves the associated decreases in plasma norepinephrine (NE) and B-type natriuretic peptide (BNP), which are objective biomarkers of chronic heart failure.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
Goop
Series A in 2015
Goop Inc. is a lifestyle brand that operates an online platform offering wellness advice, curated shopping, and lifestyle content. Founded in 2008 by Gwyneth Paltrow, Goop began as a newsletter sharing travel recommendations, health-focused recipes, and shopping finds, which has since evolved into a comprehensive lifestyle site. The platform features a selection of products including apparel, beauty items, skincare, and home goods, all sourced with an emphasis on quality and wellness. In addition to retail, Goop provides a wealth of digital content, such as beauty and makeup tips, cooking recipes, and wellness advice, along with travel information and design inspiration. By connecting its audience with expert insights and curated product offerings, Goop positions itself as a trusted resource for lifestyle enhancement.
Pager
Series A in 2015
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Stride Health
Series A in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.
MORE Health
Series A in 2015
MORE Health, Inc. operates a cloud-based physician collaboration platform aimed at connecting patients' attending doctors with specialists to collaboratively develop accurate diagnoses and optimal treatment plans. The platform encompasses a comprehensive clinical database, including medical history, hospital records, lab results, and medical imaging, as well as discussion tools that facilitate HIPAA-compliant video conferencing. In addition to these features, MORE Health offers a patient portal for personal health records, an Overseas Co-Diagnosis service for international patients, and a Secure Medical Record service for traveling employees. Initially launched as a concierge service for private clients, the company now provides its services as a supplemental health benefit for U.S. companies, allowing employees to access high-quality medical consultations, including co-diagnoses and independent second opinions. Founded in 2013 and based in Foster City, California, MORE Health has established strategic alliances with notable medical institutions, aiming to serve patients globally and provide access to top medical expertise during critical health decision-making.
Mirna Therapeutics
Series D in 2015
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
Stride Health
Seed Round in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.
U.S. Renal Care
Private Equity Round in 2015
U.S. Renal Care is a healthcare service provider that focuses on serving patients in dialysis facilities. It provides services to more than 25,000 patients in 335 dialysis facilities in 32 states and the Territory of Guam. The company has a business model, developing, and operating dialysis centers in joint venture partnerships with local nephrologists. U.S. Renal Care was founded in 2000 by Christopher Brengard and Jack Harrington and it is based in Plano, Texas.
Dermira
Series C in 2014
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
Lumena Pharmaceuticals
Series B in 2014
Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.
Pinetree
Series A in 2014
Pinetree specializes in providing professional home care services for senior citizens in China. Founded in 2004 and based in Beijing, the company offers a range of services, including home care, wellness, and insurance, aimed at enhancing the physical and mental well-being of its clients. By facilitating integrated and restorative care, Pinetree helps bridge the gap between hospitals, community health centers, and the homes of individuals, thereby promoting long-term health and independence for seniors. The company's services are designed to adapt to various stages of life and health conditions, ultimately reducing medical care expenses and fostering greater confidence in living independently. Pinetree partners with commercial entities to deliver its comprehensive offerings effectively.
CVRx
Series F in 2013
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Dermira
Series B in 2013
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
Cardioxyl Pharmaceuticals
Series B in 2012
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
Mirna Therapeutics
Series C in 2012
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
Bravo Health
Series A in 2012
Bravo Health, Inc. is a managed care provider that specializes in offering Medicare Advantage plans, including options tailored for special needs populations such as those receiving institutional care or individuals with chronic health conditions. The company also provides private fee-for-service plans, allowing members the flexibility to choose their healthcare providers, as well as Part D prescription drug plans for those requiring medication coverage. Bravo Health serves members across several states, including Delaware, Maryland, Pennsylvania, Texas, New Jersey, and Washington, D.C., and extends its prescription drug plans to 43 states. Founded in 1996 and based in Baltimore, Maryland, the company was formerly known as Elder Health, Inc.
PatientKeeper
Venture Round in 2012
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
CareZone
Series A in 2012
CareZone is a healthcare platform that simplifies personal healthcare management and pharmacy delivery services. It offers tools to automate prescription refill reminders, track medical appointments, and manage health information for individuals and families. The platform allows users to coordinate care effectively by providing controlled access for family members and caregivers. By consolidating healthcare tasks into a single interface, CareZone enhances the ability of users to organize their health needs and streamline communication among those involved in their care.
PatientKeeper
Venture Round in 2011
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
Dermira
Series A in 2011
Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.
Nektar Therapeutics
Post in 2011
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, with additional operations in Huntsville, Alabama, and Hyderabad, India. The company focuses on researching and developing investigational drugs for oncology, immunology, and virology, alongside a portfolio of partnered approved medicines. Its clinical pipeline includes notable candidates such as NKTR-181 for chronic low back pain, ONZEALD for advanced metastatic breast cancer, and Bempegaldesleukin, designed to enhance cancer-killing T cell activity. Nektar is also developing therapies for autoimmune diseases, including NKTR-358, and various other conditions like hemophilia A, opioid-induced constipation, and systemic lupus erythematosus. The company's strategy involves leveraging the immune system to combat cancer and restore immune balance in autoimmune disorders. Nektar has established collaboration agreements with several major pharmaceutical companies, enhancing its research capabilities and development efforts. Incorporated in 1990, Nektar Therapeutics continues to advance its innovative drug candidates through various stages of clinical trials.
Cardioxyl Pharmaceuticals
Venture Round in 2010
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
PatientKeeper
Series G in 2009
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
Epizyme
Series B in 2009
Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.
GoodGuide
Series B in 2009
GoodGuide.com offers a comprehensive database that provides consumers with reliable information about the health, environmental, and social impacts of over 60,000 products, including personal care items and household cleaners. The platform enables users to assess the safety and sustainability of products through expert-vetted ratings, making it easier to choose items that align with their values. GoodGuide emphasizes transparency by revealing what is behind product labels and offers personalized recommendations based on individual preferences. In addition to its extensive product information, GoodGuide has recently expanded its offerings to include guidance on food and plans to add data on toys, electronics, and automobiles, positioning itself as a leading resource for consumers seeking safe and environmentally friendly products. The service is accessible online and via mobile devices, ensuring that users can access crucial product information anytime and anywhere.
GoodGuide
Series A in 2009
GoodGuide.com offers a comprehensive database that provides consumers with reliable information about the health, environmental, and social impacts of over 60,000 products, including personal care items and household cleaners. The platform enables users to assess the safety and sustainability of products through expert-vetted ratings, making it easier to choose items that align with their values. GoodGuide emphasizes transparency by revealing what is behind product labels and offers personalized recommendations based on individual preferences. In addition to its extensive product information, GoodGuide has recently expanded its offerings to include guidance on food and plans to add data on toys, electronics, and automobiles, positioning itself as a leading resource for consumers seeking safe and environmentally friendly products. The service is accessible online and via mobile devices, ensuring that users can access crucial product information anytime and anywhere.
Acclarent
Venture Round in 2009
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.
PatientKeeper
Series F in 2008
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
CVRx
Series E in 2008
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
CVRx
Series D in 2007
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Acclarent
Series C in 2007
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.
Cardioxyl Pharmaceuticals
Series A in 2006
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
PatientKeeper
Series E in 2006
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
Acclarent
Series B in 2005
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.
PatientKeeper
Series D in 2004
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
PatientKeeper
Series B in 2000
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
PatientKeeper
Series A in 2000
PatientKeeper specializes in EHR optimization software that enhances clinical and revenue cycle workflows for healthcare providers, care teams, billers, and coders. Its solutions enable healthcare professionals to efficiently manage patient data, access clinical results, enter diagnoses and billing information, dictate notes, and write prescriptions. By serving as a system of engagement alongside existing EHR systems, PatientKeeper allows providers to seamlessly access and act on patient information using smartphones, tablets, and PCs, ultimately improving patient care and operational performance.
ppoNEXT
Venture Round in 1999
PPONEXT is a PPO services company that provides healthcare management and network services. PPONEXT offers access to a network of medical care providers, hospitals, and ancillary facilities to group health, workers' compensation, and other insurance payers in the Midwest, Texas, California, Florida, New Jersey, and Pennsylvania.
CardioThoracic Systems
Venture Round in 1995
CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.